文章：

二甲双胍联合局部疗法治疗肝癌的抗肿瘤活性：证据与未来方向

Antitumor Activity of Metformin Combined with Locoregional Therapy for Liver Cancer: Evidence and Future Directions

原文发布日期：13 September 2023

DOI: 10.3390/cancers15184538

类型: Article

开放获取: 是

英文摘要：

This article aimed to examine the effect of metformin use on improving outcomes after liver-directed therapy in patients with HCC and identify future directions with the adjuvant use of and potential therapeutic agents that operate on similar mechanistic pathways. Databases were queried to identify pertinent articles on metformin’s use as an anti-cancer agent in HCC. Eleven studies were included, with five pre-clinical and six clinical studies. The mean overall survival (OS) and progression-free survival were both higher in the locoregional therapy (LRT) + metformin-treated groups. The outcome variables, including local tumor recurrence rate, reduction in HCC tumor growth and size, tumor growth, proliferation, migration and invasion of HCC cells, HCC cell apoptosis, DNA damage, and cell cycle arrest, showed favorable outcomes in the LRT + metformin-treated groups compared with LRT alone. This systemic review provides a strong signal that metformin use can improve the tumor response after locoregional therapy. Well-controlled prospective trials will be needed to elucidate the potential antitumor effects of metformin and other mTOR inhibitors.

摘要翻译： 

本文旨在探讨二甲双胍对肝细胞癌患者接受肝脏定向治疗后疗效的改善作用，并明确其辅助应用的未来方向及作用于相似机制通路的潜在治疗药物。通过检索数据库，筛选出关于二甲双胍作为肝细胞癌抗癌药物的相关文献。共纳入11项研究，包括5项临床前研究和6项临床研究。在局部区域治疗联合二甲双胍治疗组中，平均总生存期和无进展生存期均较高。与单纯局部区域治疗相比，联合治疗组在局部肿瘤复发率、肝细胞癌肿瘤生长和体积减小、肿瘤生长、增殖、迁移和侵袭、肝细胞癌细胞凋亡、DNA损伤及细胞周期阻滞等结局指标方面均显示出更优结果。本系统综述强烈提示，二甲双胍可改善局部区域治疗后的肿瘤应答。未来需要开展严格对照的前瞻性试验，以阐明二甲双胍及其他mTOR抑制剂的潜在抗肿瘤效应。

原文链接：

Antitumor Activity of Metformin Combined with Locoregional Therapy for Liver Cancer: Evidence and Future Directions